Vestergaard P, Rejnmark L, Mosekilde L
Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus Sygehus, Tage Hansens Gade 2, 8000, Aarhus C, Denmark.
Osteoporos Int. 2006;17(6):807-16. doi: 10.1007/s00198-005-0065-y. Epub 2006 Mar 7.
Our objective was to study the association between fracture risk and the use of anxiolytics and sedatives (benzodiazepines, etc.), neuroleptics and antidepressants.
This was a case control study. All cases consisted of subjects who had sustained a fracture during the year 2000 (n=124,655). For each case, three controls (n=373,962) matched for age and gender were randomly drawn from the background population. Exposure was defined as the use of neuroleptics, antidepressants and anxiolytics/sedatives, psychiatric disease (manic depressive states, schizophrenia, other psychoses), and other confounders. The effect of dose was examined as a defined daily dose per day (DDD/day). The values referred to are confounder-adjusted.
For anxiolytics and sedatives, there was a small increase in overall fracture risk (OR: around 1.1) even with limited doses (<0.1 DDD/day). No dose-response relationship was observed for anxiolytics and sedatives. For neuroleptics, a limited increase in overall fracture risk was observed (OR: around 1.2 from <0.05 DDD/day with no dose-response relationship). For antidepressants, a dose-response relationship was observed for fracture risk (OR: increasing from 1.15, 95% CI: 1.11-1.19 at <0.15 DDD/day to 1.40, 95% CI: 1.35-1.46 for >or=0.75 DDD/day). The risk of fracture was higher with selective serotonin re-uptake inhibitors than with tricyclic antidepressants.
Small increases in fracture risk were seen with the use of anxiolytics and sedatives and neuroleptics without a dose-response relationship. The increase may be linked to an increased risk of falls. For antidepressants, a dose-response relationship was found, with a higher fracture risk for selective serotonin re-uptake inhibitors.
我们的目的是研究骨折风险与使用抗焦虑药和镇静剂(苯二氮䓬类等)、抗精神病药及抗抑郁药之间的关联。
这是一项病例对照研究。所有病例均为在2000年发生骨折的受试者(n = 124,655)。对于每个病例,从背景人群中随机抽取三名年龄和性别匹配的对照(n = 373,962)。暴露因素定义为使用抗精神病药、抗抑郁药和抗焦虑药/镇静剂、精神疾病(躁郁症、精神分裂症、其他精神病)以及其他混杂因素。剂量效应以每日限定日剂量(DDD/天)进行检验。所提及的值均为经混杂因素调整后的。
对于抗焦虑药和镇静剂,即使剂量有限(<0.1 DDD/天),总体骨折风险也有小幅增加(比值比:约为1.1)。未观察到抗焦虑药和镇静剂的剂量 - 反应关系。对于抗精神病药,总体骨折风险有有限增加(比值比:从<0.05 DDD/天起约为1.2,无剂量 - 反应关系)。对于抗抑郁药,观察到骨折风险存在剂量 - 反应关系(比值比:从<0.15 DDD/天时的1.15,95%置信区间:1.11 - 1.19增加到≥0.75 DDD/天时的1.40,95%置信区间:1.35 - 1.46)。选择性5-羟色胺再摄取抑制剂导致的骨折风险高于三环类抗抑郁药。
使用抗焦虑药和镇静剂以及抗精神病药会使骨折风险小幅增加,且无剂量 - 反应关系。这种增加可能与跌倒风险增加有关。对于抗抑郁药,发现存在剂量 - 反应关系,选择性5-羟色胺再摄取抑制剂导致的骨折风险更高。